These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29021448)

  • 41. A first report of familial visceral myopathy with additional chylous ascites in two siblings.
    Jatzko G; Lisborg P; Siebert F; Denk H; Klimpfinger M
    Scand J Gastroenterol; 1997 Feb; 32(2):187-90. PubMed ID: 9051881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytologic finding of chyloascites in lymphangioleiomyomatosis. A case report.
    Yamauchi M; Nakahara H; Uyama K; Tsujimoto A; Tamai M; Aozasa K
    Acta Cytol; 2000; 44(6):1081-4. PubMed ID: 11127739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Octreotide for therapy of chylous ascites in yellow nail syndrome.
    Widjaja A; Gratz KF; Ockenga J; Wagner S; Manns MP
    Gastroenterology; 1999 Apr; 116(4):1017-8. PubMed ID: 10092335
    [No Abstract]   [Full Text] [Related]  

  • 44. Lymphangioleiomyomatosis treatment with sirolimus.
    Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
    Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sirolimus efficacy in the treatment of critically ill infants with congenital primary chylous effusions.
    Agarwal S; Anderson BK; Mahajan P; Fernandes CJ; Margolin JF; Iacobas I
    Pediatr Blood Cancer; 2022 Feb; 69(2):e29510. PubMed ID: 34889518
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The Use of Octreotide Acetate in the Management of Refractory Chylothorax Following Surgical Treatment for Lung Cancer].
    Kawakami T; Ishida I; Sugawara T; Oura H
    Kyobu Geka; 2016 Jun; 69(6):429-32. PubMed ID: 27246125
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Refractory systemic lupus erythematosus with chylous effusion successfully treated with sirolimus: a case report and literature review.
    Banic M; Pavlisa G; Hecimovic A; Grzelja J; Anic B; Samarzija M; Jankovic Makek M
    Rheumatol Int; 2023 Sep; 43(9):1743-1749. PubMed ID: 37326666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Lymphangioma complicated by chylothorax and chylous ascites].
    Gushcha AL; Iudin VA
    Khirurgiia (Mosk); 1976 Apr; (4):120-1. PubMed ID: 948161
    [No Abstract]   [Full Text] [Related]  

  • 49. Delayed-Onset Chylous Ascites After a Living-Donor Liver Transplant: First Case Successfully Treated With Conservative Treatment?
    Chen JH; Chang CM; Lu MC; Wei CK; Yin WY
    Exp Clin Transplant; 2016 Jun; 14(3):345-8. PubMed ID: 25365187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recovery of chylous pulmonary congestion in tuberous sclerosis complex-associated lymphangioleiomyomatosis.
    Kinoshita Y; Sakamoto A; Hidaka K
    BMJ Case Rep; 2014 Oct; 2014():. PubMed ID: 25326562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human herpes virus 8-negative primary effusion lymphoma (PEL) in a patient after repeated chylous ascites and chylothorax.
    Nonami A; Yokoyama T; Takeshita M; Ohshima K; Kubota A; Okamura S
    Intern Med; 2004 Mar; 43(3):236-42. PubMed ID: 15098608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful treatment of refractory chylous effusions of unknown origin with octreotide.
    Zeller L; Etzion Y; Hertzanu Y; Schlaeffer F; Sukenik S
    Isr Med Assoc J; 2008; 10(8-9):655-6. PubMed ID: 18847174
    [No Abstract]   [Full Text] [Related]  

  • 53. Octreotide in malignant chylothorax: a case report.
    Gupta A; Singh T
    BMJ Support Palliat Care; 2016 Mar; 6(1):122-4. PubMed ID: 26644224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Octreotide as a therapeutic option for management of chylothorax.
    Al-Zubairy SA; Al-Jazairi AS
    Ann Pharmacother; 2003 May; 37(5):679-82. PubMed ID: 12708946
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Congenital fetal and neonatal visceral chylous effusions: neonatal chylothorax and chylous ascites revisited. A multicenter retrospective study.
    Bellini C; Ergaz Z; Radicioni M; Forner-Cordero I; Witte M; Perotti G; Figar T; Tubaldi L; Camerini P; Bar-Oz B; Yatsiv I; Arad I; Traverso F; Bellini T; Boccardo F; Campisi C; Dalmonte P; Vercellino N; Manikanti S; Bonioli E
    Lymphology; 2012 Sep; 45(3):91-102. PubMed ID: 23342929
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
    Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
    Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characteristics of Patients with Lymphangioleiomyomatosis and Pleural Effusion: A Systematic Review.
    Lama A; Ferreiro L; Golpe A; Gude F; Álvarez-Dobaño JM; González-Barcala FJ; Toubes ME; San José E; Rodríguez-Núñez N; Valdés L
    Respiration; 2016; 91(3):256-64. PubMed ID: 26938102
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Refractory Chylous Ascites with Chylothorax and an Umbilical Hernia in a Patient Ineligible for a Transjugular Intrahepatic Portosystemic Shunt.
    Fatah A; Audiyanto T
    Am J Case Rep; 2020 Aug; 21():e925026. PubMed ID: 32865187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Idiopathic chylous ascites in a patient with HIV infection: response to total parenteral nutrition and octreotide therapy.
    Nunes G; Fonseca C; Barosa R; Patita M; Gomes A; Botas J; Coelho H; Brito MJ; Fonseca J
    Clin J Gastroenterol; 2018 Jun; 11(3):235-239. PubMed ID: 29427281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
    Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
    Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.